Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and another hormone, may represent a significant advancement for obesity management . Preliminary human trials have demonstrated substantial decreases in body fat , potentially exceeding other obesity medications . Despite this, more study is needed to completely assess its